EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 157 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,999,452 | -19.3% | 1,141,373 | -0.6% | 0.01% | -14.3% |
Q2 2023 | $22,312,642 | -31.5% | 1,147,771 | -0.1% | 0.01% | -33.3% |
Q1 2023 | $32,580,905 | -9.4% | 1,148,429 | -6.6% | 0.02% | -19.2% |
Q4 2022 | $35,949,061 | +9.6% | 1,229,872 | -50.4% | 0.03% | +4.0% |
Q3 2022 | $32,788,756 | -48.7% | 2,479,558 | +72.5% | 0.02% | -43.2% |
Q2 2022 | $63,860,000 | -13.1% | 1,437,314 | -3.2% | 0.04% | +25.7% |
Q1 2022 | $73,512,000 | -5.5% | 1,485,404 | -2.8% | 0.04% | +9.4% |
Q4 2021 | $77,814,000 | -8.6% | 1,528,152 | +0.1% | 0.03% | -13.5% |
Q3 2021 | $85,182,000 | +30.0% | 1,527,102 | -0.2% | 0.04% | +32.1% |
Q2 2021 | $65,504,000 | -1.3% | 1,530,477 | -3.8% | 0.03% | -6.7% |
Q1 2021 | $66,396,000 | -15.8% | 1,590,710 | -6.1% | 0.03% | -18.9% |
Q4 2020 | $78,893,000 | +9.3% | 1,694,073 | -0.3% | 0.04% | -2.6% |
Q3 2020 | $72,162,000 | -11.9% | 1,698,737 | -0.5% | 0.04% | -17.4% |
Q2 2020 | $81,885,000 | +1.2% | 1,706,644 | -3.0% | 0.05% | -17.9% |
Q1 2020 | $80,937,000 | -25.1% | 1,759,494 | -2.2% | 0.06% | +1.8% |
Q4 2019 | $108,127,000 | +8.2% | 1,799,709 | +1.9% | 0.06% | +1.9% |
Q3 2019 | $99,891,000 | +1.5% | 1,765,800 | -0.1% | 0.05% | +1.9% |
Q2 2019 | $98,451,000 | +10.0% | 1,768,154 | -0.3% | 0.05% | +6.0% |
Q1 2019 | $89,531,000 | +23.8% | 1,773,252 | -1.2% | 0.05% | +8.7% |
Q4 2018 | $72,339,000 | -44.5% | 1,795,462 | -4.6% | 0.05% | -34.3% |
Q3 2018 | $130,444,000 | -8.8% | 1,881,501 | -0.5% | 0.07% | -14.6% |
Q2 2018 | $143,096,000 | +42.5% | 1,891,298 | -0.8% | 0.08% | +39.0% |
Q1 2018 | $100,446,000 | +13.2% | 1,906,360 | +14.8% | 0.06% | +7.3% |
Q4 2017 | $88,724,000 | -17.7% | 1,660,881 | -8.1% | 0.06% | -20.3% |
Q3 2017 | $107,782,000 | -25.4% | 1,807,202 | -1.3% | 0.07% | -29.6% |
Q2 2017 | $144,384,000 | – | 1,830,199 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |